With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

2.

Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.

3.

Lymph node transfer reduces arm swelling after breast cancer surgery, study shows

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot